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 Introduction 
 Currently, multidrug chemotherapy protocols 
comprise the standard of care for canine lym-
phoma. Treatment initially results in high remis-
sion rates (up to 85%), but typically they are of 
short duration (6 – 12  months). 1 Patients almost 
uniformly die from relapsing disease when neo-
plastic cells develop multidrug resistance (MDR). 2,3 
Thus, a need has arisen for complementary treat-
ments to overcome MDR and to target cells within 
lymphoma sanctuaries inaccessible to chemother-
apy. Lymphoma requires systemic treatment and 
apart from chemotherapy and immunotherapy 
only wide-field irradiation (WFI), delivered as 
either total body or sequential half-body treatments, 
is capable of treating with systemic effect. Its 
benefi t results from the exquisite radiosensitivity of 
malignant lymphocytes and lack of cross-resistance 
between chemotherapeutic drugs and radiation. 2 
 In people with non-Hodgkin ’ s lymphoma, com-
bined chemoradiation protocols have improved re-
mission durations and survival times. 3,4 WFI has also 
been effective in canine lymphoma. 5,6 However, dose-
limiting bone marrow (BM) and gastrointestinal (GI) 
toxicities  5 require careful protocol design to limit 
toxicity while maintaining effi cacy. Studies have eval-
uated the use of radiation alone  6 or in combination 
with chemotherapy  7,8 and have used either total body 
irradiation (TBI) with BM transplantation  9,10 or half-
body irradiation (HBI) without BM transplanta-
tion. 7,8 WFI has been evaluated as a rescue protocol  11 
and as consolidation of induction chemotherapy, 7,9 
but the most promising results have been obtained 
by integrating HBI with induction chemotherapy. 8 
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 Abstract 
 Thirteen dogs with previously untreated multicentric lymphoma were enrolled in a prospective 
study investigating the effects of low-dose rate total body irradiation (TBI) and chemotherapy. Dogs 
received either 6 or 8  Gy TBI in half-body fractions, 2  weeks apart. Toxicity consisted of mild to mod-
erate haematological and gastrointestinal (GI) signs. One dog died from treatment complications. 
Anorexia was noted independent of dose. Haematological toxicity was more common and more 
severe after 8  Gy treatment. GI toxicity was more likely postcaudal half-body irradiation with 8  Gy. 
Other than leukotrichia, late effects from radiation were not observed. Results indicated that haema-
tological and nonhaematological toxicity was dose dependent. However, the protocol was well 
tolerated and treatment intensifi cation using a 2-week inter-radiation interval was possible in all 
dogs treated with 6  Gy. Preliminary  survival data for these dogs were very encouraging, providing 
a strong rationale to analyse the effi cacy of low-dose rate irradiation (LDRI) in canine lymphoma. 
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Current HBI protocols attempt to modulate toxicity 
by manipulation of total dose administered, use of 
split-dose delivery or varying the inter-radiation 
treatment interval and/or eliminating the use of inter-
radiation chemotherapy. These protocols have had 
mixed results and there is no consensus as to the best 
way to limit toxicity without compromising effi cacy. 
 The goal of this study was to determine the tox-
icity profi le of an intensifi ed chemoradiation pro-
tocol, evaluating two dose levels (6 or 8  Gy) of 
low-dose rate irradiation (LDRI) given as sequen-
tial half-body fractions 2  weeks apart. Our hypoth-
esis was that LDRI would reduce toxicity to the 
lungs, BM and GI tract  allowing for a short inter-
radiation interval and a therapeutic gain. 
 Materials and methods 
 Design 
 Dogs entered had stage 3, 4 or 5 multicentric lym-
phoma diagnosed by either cytological or histopath-
ological evaluation of a lymph node. All dogs were 
clinically staged (3 – 5) at diagnosis by using the World 
Health Organization criteria for canine lymphoma. 12 
Staging included a complete blood count (CBC), 
chemistry/electrolyte panel, urinalysis, thoracic 
radiographs, abdominal ultrasound, BM aspirate 
evaluation and tumour immunophenotype [CD3 
(Serotec, Raleigh, NC, USA), Pan T-cell and CD79a 
(Dako, Carpinteria, CA, USA), Pan B-cell] as previ-
ously described. 13 Dogs were excluded if previously 
treated for lymphoma or if they had any concomi-
tant life-threatening disease. Dogs were randomized 
to receive 6  Gy (group 1,  n  =  6) or 8  Gy (group 2, 
 n  =  7) TBI interposed in a chemotherapy protocol for 
canine lymphoma. Toxicity criteria for delaying 
caudal HBI included: mean BM particle cellularity 
 £ 10%, absence of one or more BM cell lineages 
(granulocytic, erythroid, or megakaryocytic), 
neutropenia (<2500   L  − 1 ) or > 60% reduction in 
neutrophil count from baseline value, thrombocy-
topenia (<100  000   L  − 1 ) or fever (>103.5). 
 Animals 
 Thirteen dogs were enrolled with the owners ’ 
consent. Group 1 consisted of six dogs (German 
short-haired pointer, Golden retriever, German 
shepherd, Irish setter, Labrador retriever and  Tibetan 
terrier); two neutered males and four neutered 
females; median weight and age were 27.9  kg and 
7.9  years, respectively. Group 2 consisted of seven 
dogs (two Cocker spaniels, German shepherd, Golden 
retriever, Pit bull, Bull mastiff and Rottweiller 
cross); two males (one neutered) and five females 
(four neutered); median weight and age were 
29.9  kg and 7.9  years, respectively. 
 Tumour stages were as follows: group 1: 4a 
( n  =  4), 4b ( n  =  1) and 5b ( n  =  1); group 2, 3a ( n  =  1), 
4a ( n  =  3), 4b ( n  =  2) and 5b ( n  =  1). Immunophe-
notype was: group 1, B-cell lymphoma ( n  =  6); 
group 2, B-cell lymphoma ( n  =  6) and T-cell 
lymphoma ( n  =  1). 
 Treatment 
 All dogs were treated with a modifi ed Madison-
Wisconsin protocol ( Table  1 ). 14 After one cycle of 
induction chemotherapy, dogs received either 
6  Gy ( n  =  6) or 8  Gy ( n  =  7) TBI calculated at the 
midplane. Radiation was given in half-body 
fractions at a 2-week interval with cranial and 
caudal HBI scheduled for weeks 6 and 8, respec-
tively. Anaesthesia was induced with PropoFlo 
(Abbott Laboratories, North Chicago, IL, USA) and 
 Table  1.  Chemoradiation treatment protocol: Following 
week 12 repeat cycles of weeks 10 – 12 were administered at 
2-week intervals until week 28. At week 28, doxorubicin 
was substituted with actinomycin D (0.7  mg  m  − 2 ). 
Subsequent treatments were administered at 3-week 
intervals until week 52 and then every 4  weeks until 
discontinuing chemotherapy at week 104. Tx, treatment. 
 TX week  TX administered  Prescribed dose 
1  L -asparaginase 400  IU  kg  − 1 
Vincristine 0.5  mg  m  − 2 
2 Cyclophosphamide 200  mg  m  − 2 
3 Vincristine 0.7  mg  m  − 2 
4 Doxorubicin 30  mg  m  − 2 
5 None  
6 Cranial HBI 6 or 8  Gy 
7 Vincristine 0.5  mg  m  − 2 
8 Caudal HBI 6 or 8  Gy 
9 Vincristine 0.5  mg  m  − 2 
10 Cyclophosphamide 200  mg  m  − 2 
11 Vincristine 0.7  mg  m  − 2 
12 Doxorubicin 30  mg  m  − 2 
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 maintained with isofl uorane (generic). LDRI 
(8 – 14  cGy  min  − 1 ) from a Clinac 4/80 (Varian 
Medical Systems, Palo Alto, CA, USA) was given 
through bilateral opposed portals at extended 
source-to-skin distance (180 – 185  cm). Dogs were 
placed in lateral recumbency, and cranial and 
caudal fi elds were separated by a transverse line 
drawn between the dorsal spinous process of the 
13th thoracic vertebra and the xiphisternum as 
previously described. 15 These landmarks were used 
to abut the cranial and caudal fi elds at the 50% 
isodose line. All parts of the body were included 
within the treatment fi eld allowing for at least a 
2  cm beam fall-off at the edge of the patient. Bolus 
material was not used and dose corrections for 
tissue heterogeneity were not made. Source-to-
axis distance dose calculations along the central 
axis were performed using a computerized treat-
ment planning system, Prowess 2000 (Small 
Systems, Chico, CA, USA) into which hand 
measurements of patient thickness and extended 
source-to-skin distances were entered. 
 Radiation dosimetry 
 In vivo skin dose measurements were made on 
entrance and exit surfaces with a dual diode dosim-
eter, Model 22D (CNMC Instruments; Nashville, 
TN, USA). The diode was placed off central axis, 
4  cm cranial or caudal from the line delineating 
body halves, to ensure equivalent patient thickness 
at both measurement points and eliminate shape as 
a confounding factor. Skin dose was calculated by 
adding entrance and exit doses in cranial versus 
caudal locations and used to estimate the effects of 
body size and tissue heterogeneity. 
 Assessment of radiation toxicity 
 All dogs were evaluated weekly during induction 
and toxicity was graded according to VCOG guide-
lines; 16 grades 1 – 5 being mild, moderate, severe, life 
threatening and death, respectively. Haematological 
toxicity (neutropenia or thrombocytopenia) grades 
2 – 4 and GI toxicity (vomiting and diarrhoea) 
grades 3 and 4 were considered dose limiting when 
noted within the week following cranial and 
caudal HBI. 
 Haematological toxicity was evaluated by CBCs 
and cytological evaluation of BM aspirates. BM 
samples were obtained from the humerus and 
ilium 10 – 15  min before cranial and caudal HBI, 
respectively. Samples were obtained from the hu-
merus 2  weeks postcranial HBI and before caudal 
HBI to evaluate BM recovery at that site. Samples 
were obtained from the ilium 2  weeks postcaudal 
HBI to evaluate BM recovery at that site. All BM 
samples were reviewed  post hoc by a single clinical 
pathologist (M.  M.  F.). One slide from each sample 
set was used to estimate overall cellularity and for a 
200-cell differential count. Cellularity was esti-
mated based on the proportion of unit particles 
composed of haematopoietic cells (as opposed 
to fat) and expressed as a mean percentage. The 
differential count included categories for early ery-
throid (rubriblast through basophilic rubricyte), 
late erythroid (polychromatophilic rubricyte through 
metarubricyte), early granulocytic (myeloblast 
through myelocyte), late granulocytic (metamy-
elocyte through mature granulocyte), monocyte/
macrophage, well-differentiated lymphocyte, 
plasma cell and other (large cells of uncertain lin-
eage, including those with morphology consistent 
with poorly differentiated lymphocytes). Mega-
karyocyte numbers were estimated to be within 
normal limits, increased or decreased, taking into 
consideration the number of unit particles. 
 GI toxicity was evaluated by monitoring vomit-
ing and diarrhoea and by faecal occult blood (FOB) 
testing. Frequency and severity of vomiting diar-
rhoea and anorexia were monitored immediately 
after and during the entire interval between 
irradiation and subsequent chemotherapy for both 
cranial and caudal halves. FOB testing was carried 
out in all dogs receiving caudal HBI using standard 
methods. 17 Dogs were fed cottage cheese and rice 
diet for 6  days, starting 3  days before irradiation to 
obtain faecal specimens immediately before and 
3  days post-irradiation. A positive test would only 
be considered signifi cant in context of a negative 
pre-irradiation result and full owner compliance in 
feeding the prescribed diet. 
 Toxicity to the liver and kidneys was evaluated by 
fasting and postprandial bile acid analysis precaudal 
and 3  days postcaudal HBI and serum chemistry 
analysis precaudal and 1-week postcaudal HBI. 
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 Statistical analysis 
 Analysis of all continuous variables including 
peripheral cell counts and constituent BM cell lineages 
was carried out using two-way repeated measure 
ANOVA to analyse the effects of inter-radiation 
interval, radiation dose and BM sampling location. 
All data were tested for deviance from normality 
using Kolmogorov – Smirnov test. All  post hoc pair-
wise comparisons of the mean responses of the 
different groups were carried out by the Tukey ’ s test 
for analysis. A paired  t -test was used to analyse 
differences in skin doses between the cranial and 
caudal half body. Association between the skin dose 
ratio of cranial to caudal HBI and body weight was 
measured by the Pearson correlation coeffi cient. All 
computations were performed by use of statistical 
software version 11.5 (SPSS, Chicago, IL, USA). 
Statistical signifi cance was set for  P  <  0.05. 
 Analysis of outcome 
 The end-points evaluated were duration of remission 
and survival times. Variables examined as indica-
tors of prognosis included radiation dose, tumour 
stage and substage (a or b), immunophenotype, 
inter-radiation interval (2 or 3  weeks), remission 
status after irradiation [complete remission (CR) 
or not] and remission status during the overall 
treatment (CR or not). 
 Correlations between prognostic variables were 
analysed by use of the Pearson   2 . Duration of re-
sponse to treatment and survival time was computed 
by use of the product-limit method. Progression-free 
survival was used to analyse separately response dura-
tion in dogs that achieved CR and those that achieved 
partial remission or had stable disease. Dogs were 
censored if still alive at the time of analysis or if they 
died for any reason (including treatment toxicity) 
other than lymphoma. Actuarial estimates of survival 
and progression-free survival distributions were tested 
for statistical differences using log-rank statistics. 
 Results 
 The two groups were comparable with respect to 
clinical characteristics, tumour stage/substage and 
immunophenotype. 
 Treatment feasibility 
 Four of six (group 1) and three of seven (group 2) 
dogs received the planned treatment. Five dogs had 
a 1-week treatment delay postcranial HBI. One dog 
(group 1) died of progressive disease before caudal 
HBI. Only three of fi ve delays were associated with 
defi ned toxicity end-points. All three occurred in 
group 2 and resulted from grade 3 neutropenia 
( n  =  1) and inadequate BM particle cellularity 
( n  =  2). One delay (group 1) was because of owner 
concern with the lack of BM data and one (group 2) 
because of an inability to return for the scheduled 
caudal HBI. Two dogs in group 2 required hospi-
talization for supportive care, one with grade 
3 neutropenia postcranial HBI and the other with 
grade 4 vomiting and diarrhoea postcaudal HBI. 
The latter was ultimately killed at the owner ’ s re-
quest. Although BM and other toxicity parameters 
in the remaining dogs were not completely resolved 
before caudal HBI, none of them developed any 
complications requiring medical treatment. All 11 
dogs that survived longer than 9  weeks were treated 
with chemotherapy as scheduled in the protocol. 
 Haematological toxicity 
 CBC data from 2  weeks postcranial HBI showed 
signifi cant decreases in the concentrations of neu-
trophils, lymphocytes, and platelets compared with 
precranial HBI values ( Table  2 ). No cytopenias were 
noted in group 1 postcranial HBI but three of seven 
group 2 dogs developed grade 1 thrombocytopenia, 
one with concurrent grade 3 neutropenia ( Table  3 ). 
 CBC data from 2  weeks postcaudal HBI showed 
signifi cant decreases in the concentrations of neu-
trophils, lymphocytes and platelets compared with 
baseline precranial HBI values, but no signifi cant 
decreases in any blood cell counts compared with 
precaudal HBI treatment values ( Table  2 ). Three of 
fi ve group 1 dogs developed grade 1 thrombocyto-
penia postcaudal HBI. In group 2, fi ve of seven 
dogs developed grade 1 thrombocytopenia, three 
with concurrent neutropenia (1, grade 3; 1, grade 2 
and 1, grade 1). A sixth dog developed grade 1 neu-
tropenia without thrombocytopenia. The seventh 
dog was killed before obtaining a postcaudal HBI 
CBC ( Table  3 ). 
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 Comparison of cranial BM samples before ver-
sus after cranial HBI revealed signifi cant fi ndings 
that were independent of the radiation dose ( Table  4 ). 
The postcranial HBI sample had a decreased ratio 
of granulocytic to erythroid cells (0.37) compared 
with the precranial HBI value (1.46). Megakaryo-
cytes were interpreted to be decreased in 4 of 13 
dogs (two from each group) postcranial HBI. The 
estimated cellularity of the caudal BM sample 
collected 2  weeks postcranial HBI was signifi cantly 
higher than the cranial BM sample collected at the 
same time (60 versus 38%, respectively). No signif-
icant differences in the proportions of different cell 
types were detected between these two samples. 
 Comparison of caudal BM samples before versus 
after caudal HBI revealed signifi cant fi ndings that 
were independent of the inter-radiation interval 
(2 or 3  weeks) and radiation dose ( Table  5 ). The 
postcaudal HBI sample had a decreased ratio of 
granulocytic to erythroid cells (0.3) compared with 
the precaudal HBI value (1.0). Megakaryocytes were 
interpreted to be decreased in 9 of 12 dogs postcau-
dal HBI (three in group 1 and six in group 2). 
 Nonhaematological toxicity 
 Gastrointestinal 
 No dog vomited immediately (0 – 2  h) postcranial 
HBI or at home in the interval between irradiation 
and subsequent chemotherapy. One of fi ve (group 1) 
and four of seven (group two) dogs experienced 
 Table  2.  Periradiation CBC analysis: CBC evaluation; median (range) pre-Cr HBI, 2  weeks post-Cr HBI/pre-Cd HBI and 
2  weeks post-Cd HBI 
  Neutrophils   L  − 1  Lymphocytes   L  − 1  Platelets 10 3   L  − 1 
Pre-Cr HBI  
  6  Gy 8633 (3894 – 10061) 1131 (97 – 1534) 483 (450 – 784) 
  8  Gy 10004 (6225 – 16910) 760 (348 – 1797) 392 (279 – 757) 
Pre-Cd HBI a  
  6  Gy 3814 (2550 – 4836) 736 (544 – 825) 269 (237 – 396) 
  8  Gy 3555 (945 – 7425) 450 (270 – 828) 223 (120 – 321) 
Post-Cd HBI b  
  6  Gy 3713 (2808 – 8130) 507 (432 – 612) 162 (132 – 304) 
  8  Gy 1897 (924 – 4558) 384 (79 – 650) 114 (104 – 228) 
Normal range 3000 – 15  000 1000 – 4000 150 – 400 
 Cr HBI, cranial half-body irradiation; Cd HBI, caudal half-body irradiation. 
 a (All values)  P  <  0.001 compared with pre-Cr HBI. 
 b (All values)  P  <  0.001 compared with pre-Cr HBI. 
 Table  3.  Treatment toxicity (VCOG guidelines) 
 Toxicity 
 Grade  Grade 
 1  2  3  4  5  1  2  3  4  5 
6  Gy ( n  =  6) 8  Gy ( n  =  7) 
Postcranial HBI  
  Neutropenia  —  —  —  —  —  —  — 1  —  — 
  Thrombocytopenia  —  —  —  —  — 3  —  —  —  — 
6  Gy ( n  =  5) 8  Gy ( n  =  7) 
Postcaudal HBI  
  Neutropenia  —  —  —  —  — 2 1 1  —  — 
  Thrombocytopenia 3  —  —  —  — 5  —  —  —  — 
  Vomiting 1  —  —  —  — 2  — 1 1  — 
  Diarrhoea  —  —  —  —  —  —  —  — 1  — 
  Anorexia 1 1 3  —  — 1 2 4  —  — 
  Lethargy  — 4 1  —  — 1 4 1 1  — 
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grade 1 vomiting immediately postcaudal HBI. Of 
these fi ve dogs, zero of one (group 1) and two of 
four (group 2) continued to vomit at home. One 
dog experienced grade 3 and the other grade 4 
vomiting. Diarrhoea (grade 4) manifested in 1 of 
13 dogs and was in the same dog with grade 4 vom-
iting postcaudal HBI. 
 Anorexia was noted uniformly postcaudal HBI. 
In group 1, anorexia was categorized as grade 3 
( n  =  3), grade 2 ( n  =  1) and grade 1 ( n  =  1), while in 
group 2, it was grade 3 ( n  =  4), grade 2 ( n  =  2) and 
grade 1 ( n  =  1). 
 Twelve of 13 dogs had negative FOB tests 
precaudal HBI. Two of 13 dogs had positive FOB 
tests postcaudal HBI, 1 of which was positive 
before irradiation and the other had been fed a 
meat-based diet before testing. 
 Kidney and liver 
 No dog showed any signifi cant serum biochemistry 
abnormalities including preprandial and postpran-
dial bile acids. 
 Skin 
 Eight dogs had coat changes. The specifi c contribu-
tion of irradiation and chemotherapy could not be 
determined. Changes likely to be associated with 
radiation exposure included diffuse cranial half-
body leukotrichia ( Fig.  1 ) in 2 of 11 dogs, 1 in each 
group. Two of 11 dogs had diffuse greying of the 
coat affecting both body halves. Two of 11 dogs 
experienced patchy alopecia, which resolved 
despite continued chemotherapy and 2 of 11 expe-
rienced patchy alopecia, which did not resolve 
during ongoing chemotherapy (104  weeks). 
 Dosimetry 
 The measured skin dose of the cranial half body 
was signifi cantly higher than the caudal half body 
( P  <  0.001). The average (±SEM) skin dose ratio 
(cranial:caudal) was 1.15 (±0.03). The higher skin 
dose for cranial versus caudal halves refl ects the 
increased transmission of radiation through lung 
tissue. No signifi cant association was found be-
tween increased dose to the cranial half body and 
body weight. 
 Outcome 
 The median follow-up time to last contact or death 
was 850  days. All dogs were available for remission 
and survival analysis. A negative correlation was 
found between radiation dose and substage 
( P  =  0.033), and positive correlations were found 
between stage and substage ( P  =  0.009) and 
between achieving CR and remission status before 
irradiation ( P  =  0.001). 
 The median remission duration was 1126  days 
(SE, 287  days) and the median survival time was 
1131  days (SE, 391  days). Univariate analysis of 
 Table  4.  Comparison of cranial BM samples before and 
after cranial HBI 
  Precranial HBI  Postcranial HBI 
Particle cellularity (%) 40 38 
Early granulocytic (%) 7 7 
Late granulocytic (%) 50 18 a 
Early erythroid (%) 10 16 a 
Late erythroid (%) 29 52 a 
 a Signifi cant difference from pre-HBI value. 
 Table  5.  Comparison of caudal BM samples before and 
after caudal HBI 
  Precaudal HBI  Postcaudal HBI 
Particle cellularity (%) 60 19 a 
Early granulocytic (%) 8 3 a 
Late granulocytic (%) 37 16 a 
Early erythroid (%) 12 13 
Late erythroid (%) 33 51 
 a Signifi cant difference from pre-HBI value. 
  
 Figure  1.  Radiation fi eld-associated leukotrichia. 
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progression-free survival revealed that remission 
status after completion of irradiation protocol was 
signifi cantly associated with duration of response 
and prognosis ( P  =  0.03) ( Fig.  2 ). In dogs that were 
in CR before irradiation, the 1-year and 3-year 
progression-free survival rates were 89 (SE, 10.4%) 
and 64% (SE, 16.9%). Although median survival 
times were longer in dogs that were in CR before 
irradiation (median not reached) than in dogs that 
were not in CR (median 93  days), the difference in 
survival distribution was not statistically signifi cant 
( P  =  0.08) ( Fig.  3 ). None of the other variables eval-
uated was found to affect remission or survival. 
However, these fi ndings should be interpreted 
cautiously because of the low statistical power 
because of the small sample size. 
 Discussion 
 This LDRI protocol attempted to enhance the ther-
apeutic gain of a combined chemoradiation proto-
col by shortening the inter-radiation interval. 
Classically, decreased tissue toxicity associated with 
LDRI results from the repair of sublethal damage 
that occurs during prolonged radiation exposure. 18 
We hypothesized that LDRI would decrease nor-
mal tissue toxicity and increase the therapeutic 
index by minimizing tumour cell repopulation 
during a shortened inter-radiation interval. A dose 
rate of 8 – 14  cGy  min  − 1 was selected based on 
previously published data. 17,18 This resulted in 
treatment times ranging between 60 and 80  min. A 
lower dose rate was considered but would have 
resulted in signifi cantly prolonged treatment time 
and increased anaesthesia costs thought to be 
impractical. 
 Decreases in the concentrations of circulating 
neutrophils, platelets and lymphocytes were evi-
dent postcranial HBI and persisted postcaudal 
HBI; however, dose-limiting cytopenias were rare 
and only occurred in group 2. Cytopenias were 
more common postcaudal HBI in both groups but 
were more frequent and severe in group 2. Our 
assumption is that cytopenias were a direct result 
of radiation-induced damage to BM haematopoi-
etic elements and impaired granulopoiesis and 
thrombopoiesis. The increased frequency postcau-
dal HBI most likely refl ects the fact that caudal HBI 
always followed cranial HBI resulting in  diminished 
BM stores with which to replenish cell populations. 
With respect to severity, haematological fi ndings 
were consistent with those of other investigators 
 7,8,19 where fractionation and/or prolonged inter-
treatment intervals were used. 
 The effect of dose rate versus fractionation has 
been evaluated in dogs. 5,17 LDRI resulted in the 
best therapeutic ratio of inactivation of  haemato-
poietic  precursor cells to acute toxicity. While 
inactivation and recovery of precursor cells was not 
dose rate dependent, the nadirs of leucocyte, 
lymphocyte and platelet counts were lower in dogs 
treated at higher dose rates. 5 Additionally, it was 
shown that a single dose of TBI administered at 
60  cGy  min  − 1 versus 10  cGy  min  − 1 was more BM 
toxic as indicated by more profound nadirs in 
  
 Figure  2.  Progression-free survival rate: comparison of 
dogs in CR versus PR or SD postcaudal HBI. CR, complete 
remission; PR, partial remission; SD, stable disease 
( P  =  0.03). 
  
 Figure  3.  Survival rate: comparison of dogs in CR versus 
PR or SD postcaudal HBI. PR, partial remission; SD, stable 
disease ( P  =  0.08). 
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peripheral blood counts. 19 This result agreed with a 
number of previous studies showing greater organ 
toxicity with higher dose rates. 18,19 In dogs, toxicity 
to the lymphoid system increases signifi cantly 
when dose rate is increased by 1 log. 20 
 BM cells represent the most radiosensitive 
mammalian cells. 18  In vitro experiments have 
demonstrated that BM has virtually no capacity for 
repair. 18 However, it has been demonstrated that 
only 10% of the body ’ s BM needs to be spared to 
allow the otherwise lethally irradiated portion to be 
repopulated. 21 Repopulation may occur as a result 
of surviving stem cells within the irradiated 
BM compartment or through migration of stem 
cells from the unexposed BM compartment. 22,23 
 Humerus BM particle cellularity  ³ 10% was set as 
our threshold for the administration of caudal HBI, 
although in most instances cellularity exceeded this 
value. Only two dogs had treatment delay because 
of inadequate BM cellularity. BM toxicity of frac-
tionated versus single-dose TBI has been shown to 
be identical when single doses are administered at 
an LDR (10  cGy  min  − 1 ). 24 As dose rate is lowered 
and treatment time is lengthened, greater cellular 
recovery (because of repair or repopulation) of 
radiation damage occurs during exposure. 18 This 
results in decreased toxicity to BM, lungs and GI 
organs. 21,23 We predict the resultant decrease in 
inter-radiation interval will outweigh any sparing 
effect of LDRI on lymphoid tissue resulting in an 
overall therapeutic gain. 
 The lack of difference in estimated cellularity of 
humerus BM samples before and after cranial HBI 
was an unexpected fi nding, especially in light of the 
CBC fi ndings. The most likely explanation for this 
is that there was decreased cellularity, mostly 
because of decreased granulopoeisis, in the cra-
nial marrow compartment postcranial HBI, but we 
failed to detect it because of the limitations of aspi-
ration cytology (core biopsy and histopathology is 
more reliable, 25 but was not carried out). 
 The estimated cellularity of the caudal BM sam-
ples before caudal HBI was signifi cantly higher 
than the cellularity of the cranial samples before 
cranial HBI. Although this may indicate compen-
satory hyperplasia in the caudal compartment after 
cranial HBI, the study design did not allow us 
to test this hypothesis. It is also possible that we 
underestimated the cellularity of the cranial BM 
samples before HBI, which may explain why no 
apparent difference in the cellularity of cranial BM 
samples before and after cranial HBI was noted. 
 Although the changes were not statistically 
signifi cant, neutrophil, lymphocyte and platelet 
counts all decreased in both treatment groups 
following caudal HBI, consistent with the signifi -
cant decrease in estimated cellularity of caudal BM 
samples obtained precaudal and postcaudal HBI. 
Compensatory hyperplasia in the cranial compart-
ment after caudal HBI may have prevented a more 
dramatic decrease in peripheral cell counts, but 
direct evidence of this is lacking. 
 The lower proportions of granulocytic cells in 
BM samples post-HBI compared with pre-HBI, 
and the lack of a similar pattern in the erythroid 
lineage, suggests that the granulocytic lineage was 
more susceptible than the erythroid lineage to 
radiation-induced damage. Researchers have shown 
that in people, radiation does not signifi cantly alter 
the function or longevity of mature erythrocytes 
and nucleated erythroid precursors appear more 
radiation resistant than granulocytic precursors. 26 
Our data suggest that the canine erythroid lineage 
is also more resistant than the granulocytic lineage 
to the effects of ionizing radiation. 
 In this study, thrombocytopenia and decreased 
megakaryocyte numbers were more common post-
caudal HBI but was mild in both groups. In people, 
thrombocyte lifespan is only 8 – 9  days in peripheral 
blood, but the levels are not immediately affected 
by ionizing radiation because of a protracted mega-
karyocyte response. Only the earliest progenitors 
undergo immediate lethal changes. Most of the 
remaining megakaryocytes, although damaged, 
will continue some degree of maturation and some 
will be capable of limited platelet production. This 
provides a slowly diminishing source of platelets. 26 
 Acute toxicity of TBI other than diminished 
haematopoiesis is primarily GI. The progression of 
the GI syndrome post-irradiation is characterized 
by anorexia, abdominal cramping, vomiting, diar-
rhoea, lethargy, dehydration and infection. 26 In 
this study, GI signs were much more likely after 
caudal HBI, which likely refl ects that no signifi cant 
portion of the GI tract was included within the 
cranial half-body fi eld. We speculate that vomiting 
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immediately after caudal HBI was likely a  serotonin-
mediated event because of direct action of ionizing 
radiation on enterochromaffi n cells of the GI 
lining. 27 The acuteness of onset is consistent with 
the prodromal stage of GI syndrome. The two dogs 
that continued to vomit at home may still have 
been exhibiting signs of the prodromal stage, 
bordering on the latent stage of GI syndrome at 
which point cells lining the GI tract are dying. 28 
Apart from anorexia, very little GI toxicity (vomit-
ing or diarrhoea) was noted in this study, but was 
more common in group 2. Anorexia, starting 
within 1 – 2  days postcaudal HBI was likely associ-
ated with the prodromal stage. We speculate that 
prolonged anorexia, 8 – 10  days post-irradiation was 
likely associated with general malaise secondary to 
myelosuppression. No dog showed evidence of GI 
ulceration as evaluated by FOB testing. In dogs, 
LDRI has been signifi cantly associated with 
increased treatment tolerance with respect to GI 
toxicity. 5,28 Kidney and liver toxicity were not 
 clinically relevant issues in this study. 
 Field-related alopecia has been reported in dogs 
undergoing WFI. 8 In this study, radiation-related 
leukotrichia was seen in two dogs. Increased skin 
surface dose measured in the cranial half body 
most likely refl ects a greater transmission of radia-
tion through less dense air-fi lled lung. Clinical 
evidence of lung toxicity (pneumonitis and/or 
fi brosis) was not observed in this study but may 
have occurred at a subclinical level. Although this 
study mostly evaluated acute toxicity, long-term 
follow-up in all dogs was available as all dogs 
returned for follow-up chemotherapy until com-
pletion of the protocol at 2  years or death. During 
the entire evaluation period, no dog showed any 
evidence of clinically signifi cant kidney, liver, lung 
or BM late effects. 
 Current TBI protocols involve sequential HBI 
with either 8  Gy (two consecutive 4  Gy fractions 
24  h apart)  7,8,29 or 6  Gy (single fraction)  29 with a 
3- to 4-week inter-radiation interval. These proto-
cols use high dose rate irradiation and presumably 
rely on prolonged inter-radiation intervals to avoid 
signifi cant toxicity. While successful in limiting 
toxicity, these protocols have not resulted in a sig-
nifi cant improvement in survival. 7,8 This is most 
likely because of the rapid doubling time (28 – 32  h) 
of lymphoma cells  30,31 and subsequent repopula-
tion of the irradiated half body by cells mobilized 
from nonirradiated tissues. Our study attempted 
to minimize tumour repopulation by shortening 
the inter-radiation interval to 2  weeks and by 
administering chemotherapy in between radiation 
doses. The vincristine dose (weeks 7 and 9) was 
decreased as a precautionary measure to minimize 
the risk of severe BM toxicity following irradiation. 
Our results suggest that this protocol allows for the 
maximal benefi t of combined chemoradiotherapy, 
although it should be noted that high dose rate pro-
tocols with 2-week inter-radiation intervals have not 
been directly evaluated and may also be feasible. 
 As with most cancer therapies, it has been shown 
that the initial performance status of patients 
treated with HBI is one of the strongest determi-
nants of outcome. 32 Patients with more complete 
initial responses ultimately have longer overall 
median survival times. 33 This was consistent with 
our results as two of three dogs that did not achieve 
CR postcaudal HBI died within 153  days, whereas 
the third dog had an indolent form of the disease 
associated with improved survival. In this study, 
radiation was performed at weeks 6 and 8, respec-
tively, as most patients on multidrug protocols will 
have achieved CR by this time. No benefi t could be 
seen to waiting any longer before initiating the 
respective HBI treatments. We also speculated that 
a relatively fresh BM would be more likely to 
recover from radiation exposure than marrow 
that had received multiple insults from previous 
chemotherapy exposures. 
 Our results show that this LDRI protocol was 
generally well tolerated in dogs treated with 6  Gy. 
Treatment intensifi cation using a short 2-week 
inter-radiation interval was possible in all dogs 
treated with 6  Gy. Our preliminary data suggest 
that signifi cant improvements in fi rst remission 
duration and survival time can be obtained with 
combination treatment protocols. One important 
limitation of this study is the small number of 
patients evaluated especially in light of several 
treatment delays that occurred. Currently, a larger 
clinical trial is underway to evaluate the effi cacy of 
this protocol. Another aspect to evaluate is whether 
or not inter-radiation vincristine is benefi cial or if 
it contributes to radiation treatment delays. 
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